FDA Raises Concerns Over Animal Lab Issues at Musk’s Neuralink

In a recent exclusive report, it has been revealed that the U.S. Food and Drug Administration (FDA) has cited Elon Musk’s Neuralink over issues pertaining to record-keeping and quality controls in animal experiments. This development comes shortly after Neuralink announced its clearance to conduct human trials for its brain implants.

The FDA inspectors uncovered lapses in quality control at Neuralink’s California-based animal research facility during inspections conducted from June 12-22 last year. Notably, a similar inspection at the company’s Texas facility did not uncover any problems. The findings, obtained from agency records by Redica Systems, a data analytics company, highlighted issues such as missing calibration records for essential instruments and deficiencies in quality assurance protocols.

According to Jerry L. Chapman, a senior quality expert with Redica Systems, these findings underscore a lack of attention to detail within the company. Such lapses could potentially affect the reliability of scientific data crucial for the development of Neuralink’s brain implant technology.

The brain implant, designed to aid patients paralyzed by spinal cord injuries or ALS, relies on data derived from animal research to support its progression to human trials. However, concerns regarding the treatment of animals at Neuralink had previously been raised by both internal staff complaints and external advocacy groups.

While the U.S. Department of Agriculture (USDA) had investigated potential animal welfare violations at Neuralink, it found no further breaches beyond a previously reported incident in 2019. However, the FDA, which has its own requirements for animal research under Good Laboratory Practice standards, conducted inspections to ensure the reliability and integrity of the data presented by Neuralink in its human trial application.

Despite these concerns, Neuralink proceeded with its human trials, with Musk announcing the clearance for human testing in May. The FDA, while acknowledging the issues identified during the inspection, did not find them significant enough to prevent Neuralink from proceeding with its trials. The agency emphasized its commitment to monitoring the safety of participants enrolled in the study.

However, some experts and advocacy groups, such as the Physicians Committee for Responsible Medicine, have criticized the FDA’s decision not to inspect Neuralink prior to approving its human trials. Victor Krauthamer, a former FDA official, emphasized the importance of upholding fundamental requirements to ensure the safety and reliability of clinical trials, particularly those involving innovative technologies such as brain implants.

Neuralink has yet to respond to inquiries regarding the FDA inspection. However, the scrutiny over animal lab issues raises questions about the company’s commitment to ethical research practices as it advances its groundbreaking technology.


Joan David-Leonhard

Joan David Leonhard is a recent Pharm.D graduate with a strong passion for the pharmaceutical industry and a particular interest in pharmaceutical media and communication. Her brief internship experience includes roles in pharmacy where she built strong patient-pharmacist relationships and a pharmaceutical media internship where she actively contributed to drug information articles, blog posts, social media engagement, and various media projects.
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker